Advances in Targeted Therapy of Non-small Cell Lung Cancer with EGFR Combined With P53 Gene Mutation

Abstract

Non-small cell lung cancer (NSCLC) is currently the leading cause of cancer death worldwide. NSCLC patients with epidermal growth factor receptor (EGFR) mutations were treated with EGFR-tyrosine kinase inhibitor (TKI), but EGFR mutations combined with other genes had a shorter survival. However, the P53 gene mutation is a common combined mutation in patients with NSCLC with EGFR gene mutation. This review summarizes the development of targeted NSCLC for EGFR with P53 mutations.